[Immunomodulin efficacy in treatment of celiac disease in children].
Overall forty patients with celiac disease who ranged from 1 to 10 years old were kept under medical observation. Measured in the above patient population were the following parameters for cellular immunity: the content of T-, B- lymphocytes and of subpopulation of T-lymphocytes. In all patients, the content of T- and B-lymphocytes was reduced. 18 children received immunomodulin as a corrective measure in injections and a supporting dose in tablets over two months. There was an improvement in clinical symptomatology of the condition that was particularly apparent in the long-term results in the presence of increased values for T-lymphocytes in the group of patients having received immunomodulin against the background of basic therapy.
Kamilova
A T
AT
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology; D002446:Celiac Disease / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D018655:Lymphocyte Count; D009930:Organic Chemicals; D013491:Suppressor Factors, Immunologic / Q000378:metabolism; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology
D000276:Adjuvants, Immunologic; D009930:Organic Chemicals; D013491:Suppressor Factors, Immunologic; C404023:immunomodulin